ESTRO 2023 - Abstract Book

S1159

Digital Posters

ESTRO 2023

BMI: body mass index, cT stage: clinical tumor stage, cN stage: clinical nodal stage, International Federation of Gynecology and Obstetrics (FIGO) HB: hemoglobin. Statistically significant p-values are shown in bold Conclusion Our study suggests a limited role of systemic inflammation markers in predicting prognosis in LACC pts undergoing ChRT, while confirming the dramatically negative impact of anemia in this setting. However, further studies are underway to evaluate: i) the impact of inflammation markers assessed after ChRT; ii) the possible correlation between inflammation markers and sarcopenia and the predictive role of their combination in this setting.

PO-1433 Outcomes after adjuvant sequential chemotherapy and radiotherapy for high-risk endometrial cancer

R. Fullerton 1 , M. Zahra 1 , A. Stille 2 , J. Morgan 2

1 Edinburgh Cancer Centre , Clinical Oncology , Edinburgh , United Kingdom; 2 Edinburgh Cancer Centre, Clinical Oncology, Edinburgh, United Kingdom Purpose or Objective We aimed to review cause specific survival (CSS) and recurrence patterns for high-risk endometrial cancer patients within our institution who postoperatively received sequential adjuvant chemotherapy (6 cycles) followed by adjuvant pelvic radiotherapy (EBRT 45Gy +/- VBT). All patients met PORTEC-3 entry criteria. Materials and Methods Data was retrospectively reviewed for patients between 2011 and 2018. High-risk endometrial cancer was defined as endometrioid endometrial cancer stage I, grade 3 with >50% myometrial invasion or LVSI, stage II and III or non-endometroid (serous or clear cell) histology stage I to III. FIGO 2009 staging was used. 5-year CSS was calculated using the Kaplan-Meier method. Analysis was performed using Microsoft Excel and SPSS Software. Results 138 patients met the criteria. Median age was 67(37-86). 37(26.8%) had stage I disease, 36(26.1%) stage II and 65(47.1%) stage III. 80(58.0%) had endometrioid endometrial cancer, 55(39.9%) serous and 3(2.17%) clear cell. Median follow-up was 51.1months (IQR30.3-61.2). 51(37.0%) patients died during the follow-up period. 40 (32.6%) were endometrial cancer specific deaths. Overall 5yr CSS was 73.3%. This was 77.3%, 84% and 63.4% in stage I, II and III disease respectively. 5yr CSS was better for those with endometrial adenocarcinoma (80.6%) than non-endometroid tumours (64.6%). 5yr CSS depended on grade (grade 1 90.9%, grade 2 76.6% and grade 3 69.9%). 5yr CSS for those under 60 years was 82.9% compared with 69.5% for those older. 45 patients (34.7%) recurred. 42(93.3%) had distant metastasis at time of their first recurrence. Of these 10(23.8%) had simultaneous pelvic recurrence and 1(2.4%) had simultaneous vaginal recurrence.